Immutep halts late-stage trial for lead asset due to interim analysis.

Immutep's stock fell 78% after an interim analysis forced the company to halt a late-stage trial for its lead asset, eftilagimod alfa, in collaboration with Merck. The analysis revealed that the drug failed to meet its primary efficacy endpoint in patients with advanced melanoma. The trial's halt and disappointing results are significant setbacks for Immutep.